10% Owner Deep Track Capital Buys $10M in Pre-Funded Warrants Following Private Placement
LBRX sits 81% above its 52-week low of $13.36.
Summary
Deep Track Capital, a 10% owner, acquired over $10 million in pre-funded warrants in LB Pharmaceuticals, demonstrating significant participation in the recently announced private placement.
Key Events · Ownership and Investor Activity · LBRX
-
Significant Insider Purchase
Deep Track Capital, a 10% owner, acquired $10,000,004 worth of pre-funded warrants.
-
Participation in Private Placement
This purchase follows the company's announcement of a $100 million private placement on February 5, 2026, indicating strong investor confidence.
-
Warrants Priced Favorably
The pre-funded warrants were acquired at $21.17 per unit, close to the current stock price of $24.22 and near the 52-week high.
Analysis · LBRX · Life Sciences
This Form 4 details a substantial investment by David Kroin and associated Deep Track entities, who are 10% owners of LB Pharmaceuticals. The acquisition of $10 million in pre-funded warrants on February 6, 2026, represents a significant portion of the $100 million private placement announced just one day prior on February 5, 2026. This strong participation by a major institutional investor signals confidence in the company's strategic direction and the success of its capital raise, especially as the stock trades near its 52-week high. The purchase of pre-funded warrants at a price of $21.17 per unit, close to the current market price, further underscores this positive sentiment.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LBRX was trading at $24.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $612.7M. The 52-week trading range was $13.36 to $24.95. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.